Literature DB >> 26378234

Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma.

Milcah C Scott1, Aaron L Sarver2, Hirotaka Tomiyasu1, Ingrid Cornax3, Jamie Van Etten4, Jyotika Varshney5, M Gerard O'Sullivan3, Subbaya Subramanian6, Jaime F Modiano7.   

Abstract

We previously identified two distinct molecular subtypes of osteosarcoma through gene expression profiling. These subtypes are associated with distinct tumor behavior and clinical outcomes. Here, we describe mechanisms that give rise to these molecular subtypes. Using bioinformatic analyses, we identified a significant association between deregulation of the retinoblastoma (RB)-E2F pathway and the molecular subtype with worse clinical outcomes. Xenotransplantation models recapitulated the corresponding behavior for each osteosarcoma subtype; thus, we used cell lines to validate the role of the RB-E2F pathway in regulating the prognostic gene signature. Ectopic RB resets the patterns of E2F regulated gene expression in cells derived from tumors with worse clinical outcomes (molecular phenotype 2) to those comparable with those observed in cells derived from tumors with less aggressive outcomes (molecular phenotype 1), providing a functional association between RB-E2F dysfunction and altered gene expression in osteosarcoma. DNA methyltransferase and histone deacetylase inhibitors similarly reset the transcriptional state of the molecular phenotype 2 cells from a state associated with RB deficiency to one seen with RB sufficiency. Our data indicate that deregulation of RB-E2F pathway alters the epigenetic landscape and biological behavior of osteosarcoma.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E2F transcription factor; chromatin remodeling; gene expression; osteosarcoma; retinoblastoma protein (pRb, RB)

Mesh:

Substances:

Year:  2015        PMID: 26378234      PMCID: PMC4653667          DOI: 10.1074/jbc.M115.679696

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Chromatin remodeling and Rb activity.

Authors:  J W Harbour; D C Dean
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

Review 2.  The regulation of E2F by pRB-family proteins.

Authors:  N Dyson
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

Review 3.  Clues to immune function and oncogenesis provided by events that activate the cell cycle machinery in normal human T cells.

Authors:  C G Chitko-McKown; J F Modiano
Journal:  J Leukoc Biol       Date:  1997-10       Impact factor: 4.962

4.  Collective inhibition of pRB family proteins by phosphorylation in cells with p16INK4a loss or cyclin E overexpression.

Authors:  S Ashizawa; H Nishizawa; M Yamada; H Higashi; T Kondo; H Ozawa; A Kakita; M Hatakeyama
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

5.  Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.

Authors:  Milcah C Scott; Aaron L Sarver; Katherine J Gavin; Venugopal Thayanithy; David M Getzy; Robert A Newman; Gary R Cutter; Kerstin Lindblad-Toh; William C Kisseberth; Lawrence E Hunter; Subbaya Subramanian; Matthew Breen; Jaime F Modiano
Journal:  Bone       Date:  2011-05-15       Impact factor: 4.398

Review 6.  Cross talk from pets to people: translational osteosarcoma treatments.

Authors:  Stephen J Withrow; Ross M Wilkins
Journal:  ILAR J       Date:  2010

Review 7.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Rb regulates fate choice and lineage commitment in vivo.

Authors:  Eliezer Calo; Jose A Quintero-Estades; Paul S Danielian; Simona Nedelcu; Seth D Berman; Jacqueline A Lees
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

Review 9.  A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.

Authors:  G Ranieri; C D Gadaleta; R Patruno; N Zizzo; M G Daidone; M G Hansson; A Paradiso; D Ribatti
Journal:  Crit Rev Oncol Hematol       Date:  2013-04-03       Impact factor: 6.312

10.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences.

Authors:  Jeremy Goecks; Anton Nekrutenko; James Taylor
Journal:  Genome Biol       Date:  2010-08-25       Impact factor: 13.583

View more
  13 in total

1.  Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.

Authors:  David A Largaespada; Jaime F Modiano; Subbaya Subramanian; Milcah C Scott; Nuri A Temiz; Anne E Sarver; Rebecca S LaRue; Susan K Rathe; Jyotika Varshney; Natalie K Wolf; Branden S Moriarity; Timothy D O'Brien; Logan G Spector; Aaron L Sarver
Journal:  Cancer Res       Date:  2017-10-24       Impact factor: 12.701

2.  Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning.

Authors:  Kelly M Makielski; Alicia J Donnelly; Ali Khammanivong; Milcah C Scott; Andrea R Ortiz; Dana C Galvan; Hirotaka Tomiyasu; Clarissa Amaya; Kristin A Ward; Alexa Montoya; John R Garbe; Lauren J Mills; Gary R Cutter; Joelle M Fenger; William C Kisseberth; Timothy D O'Brien; Brenda J Weigel; Logan G Spector; Brad A Bryan; Subbaya Subramanian; Jaime F Modiano
Journal:  Lab Invest       Date:  2021-09-06       Impact factor: 5.662

3.  Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.

Authors:  Antonella Borgatti; Joseph S Koopmeiners; Aaron L Sarver; Amber L Winter; Kathleen Stuebner; Deborah Todhunter; Anthony E Rizzardi; Jonathan C Henriksen; Stephen Schmechel; Colleen L Forster; Jong-Hyuk Kim; Jerry Froelich; Jillian Walz; Michael S Henson; Matthew Breen; Kerstin Lindblad-Toh; Felix Oh; Kristy Pilbeam; Jaime F Modiano; Daniel A Vallera
Journal:  Mol Cancer Ther       Date:  2017-02-13       Impact factor: 6.009

4.  Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior.

Authors:  Milcah C Scott; Hirotaka Tomiyasu; John R Garbe; Ingrid Cornax; Clarissa Amaya; M Gerard O'Sullivan; Subbaya Subramanian; Brad A Bryan; Jaime F Modiano
Journal:  Dis Model Mech       Date:  2016-11-03       Impact factor: 5.758

5.  Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.

Authors:  Sridhar Murahari; Aimee L Jalkanen; Samuel K Kulp; Ching-Shih Chen; Jaime F Modiano; Cheryl A London; William C Kisseberth
Journal:  BMC Cancer       Date:  2017-01-21       Impact factor: 4.430

6.  Evaluation of P16 expression in canine appendicular osteosarcoma.

Authors:  B G Murphy; M Y Mok; D York; R Rebhun; K D Woolard; C Hillman; P Dickinson; K Skorupski
Journal:  BMC Vet Res       Date:  2017-06-20       Impact factor: 2.741

7.  Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma.

Authors:  Lauren J Mills; Milcah C Scott; Pankti Shah; Anne R Cunanan; Archana Deshpande; Benjamin Auch; Bridget Curtin; Kenneth B Beckman; Logan G Spector; Aaron L Sarver; Subbaya Subramanian; Todd A Richmond; Jaime F Modiano
Journal:  Bone       Date:  2020-10-27       Impact factor: 4.398

Review 8.  Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.

Authors:  Jyotika Varshney; Milcah C Scott; David A Largaespada; Subbaya Subramanian
Journal:  Vet Sci       Date:  2016-01-18

9.  Associations of Socioeconomic Status, Public vs Private Insurance, and Race/Ethnicity With Metastatic Sarcoma at Diagnosis.

Authors:  Brandon J Diessner; Brenda J Weigel; Paari Murugan; Lin Zhang; Jenny N Poynter; Logan G Spector
Journal:  JAMA Netw Open       Date:  2020-08-03

10.  Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients.

Authors:  Owen T M Chan; Hideki Furuya; Ian Pagano; Yoshiko Shimizu; Kanani Hokutan; Lars Dyrskjøt; Jørgen Bjerggaard Jensen; Per-Uno Malmstrom; Ulrika Segersten; Filip Janku; Charles J Rosser
Journal:  Oncotarget       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.